Disclosures for "Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial"